Prevention and treatment of venous thromboembolism in cancer patients: project of clinical guidelines

Main Article Content

S. M. Kozhukhov
N. V. Dovganich
I. I. Smolanka
I. A. Kryachok
O. F. Ligirda


Cancer-associated thrombosis is an actual issue in the intersection of cardiology and oncology. Active cancer
counts for approximately 20 % of the total number of cases of venous thromboembolism (VTE), and VTE is one of the leading cause of death in cancer patients, second only to cancer progression. VTE in cancer has some features that distinguish it from other VTE cases. The combination of cancer-related, treatment-related and patient-related factors increases their overall risk of VTE. The experts of the Cardio-Oncology working group have created a practical approach guideline for the management of VTE in cancer patients based on a multi-disciplinary strategy, ESMO, ASCO recommendations. This document has collected information on VTE, bleeding events and treatment modalities in cancer patients that may be beneficial for clinicians in determining strategies of anticoagulant therapies in these patients. Clinicians of various specialties using these recommendations will be able to determine the most appropriate VTE management algorithm, taking into account the bleeding risk, the type of cancer with its treatment, and drug interactions.

Article Details


venous thromboembolism, thrombosis, oncological diseases, anticoagulant therapy


Практичні рекомендації. Діагностика та лікування гострої тромбоемболії легеневої артерії // Укр. кардіол. журн.– 2016.– Додаток 2.– C. 4.

Agnelli G., Becattini C., Meyer G. et al., on behalf of the Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated With Cancer // New Engl. J. Med.– 2020.– Vol. 382.– P. 1599–1607. doi:

Carrier M., Abou-Nassar K., Mallick R. et al. Apixaban to prevent venous thromboembolism in patients with cancer // New Engl. J. Med.– 2019.– Vol. 380.– P. 711–719. doi:

Connoly G., Khorana A. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score // Thromb. Res.– 2010.– Vol. 125.– P. 1–7. doi:

Cuker A., Arepally G., Chong B. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia // Blood. Adv.– 2018.– Vol. 27.– P. 3360–3392. doi:

Dabbouseh N., Patel J., Bergl P. Role of echocardiography in managing acute pulmonary embolism // BMJ.– Vol. 105.– P. 23. doi:

Farge D., Bounameaux H., Brenner B. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer // Lancet Oncol.– 2016.– Vol. 17.– P. e452–e466. doi:

Kamphuisen P., Lee A. Catheter-related thrombosis: lifeline or a pain in the neck? // Am. S. Hematology Education Program.– 2012.– P. 638–644. doi:

Kearon C. et al. Antithrombotic Therapy for VTE Disease. Chest Guidelines and Expert Panel Report // Chest.– 2016.– Vol. 149 (2).– P. 315–352. doi:

Key N., Khorana A., Kuderer N. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update // J. Clin. Oncol.– 2019. JCO1901461. doi:

Khorana A. Risk assessment and prophylaxis for VTE in cancer patients // Natl. Compr. Canc. Netw.– 2011.– Vol. 9.– P. 789–797. doi:

Khorana A., Kuderer N., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis // Blood.– 2008.– Vol. 111 (10).– P. 4902–4907. doi:

Khorana A., Soff G., Kakkar A. et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer // New Engl. J. Med.– 2019.– Vol. 380.– P. 720–728. doi:

Khorana A.A., Carrier M. et. al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism // J. Thromb. Thrombolysis.– 2016.– Vol. 41.– P. 81–91. doi:

Klok F.A., Barco S., Konstantinides S.V. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism // Thromb. Haemost.– 2017.– Vol. 117 (6).– P. 1164–1670. doi:

Konstantinides S., Meyer G., Becattini C. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) // Eur. Heart J.– 2019. doi:

Kozhukhov S., Dovganych N., Smolanka I., Lyhyrdа O. Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology // OncoReview.– 2018.– Vol. 8, N 3.– P. A65–A69. doi:

Kraaijpoel N., Bleker S., Meyer G. et al. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an International Prospective Cohort Study and on behalf of the UPE investigators // J. Clin. Oncol.– 2019.– Vol. 37.– P. 1713–1720. doi:

Laporte S., Mismetti P., Décousus H. et al., RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry // Circul.– – Vol. 117.– P. 1711–1716. doi:

Lyman G., Khorana A., Kuderer N. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer; American Society of Clinical Oncology clinical practice guideline update // J. Clin. Oncol.– 2013.– Vol. 31 (17).– P. 2189–2204. doi:

Mandal M., Falanga A., Roila F.; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines // Ann. Oncol.– 2011.– Vol. 22.– P. vi85-vi92. doi:

McBane R., Wysokinski W., Le-Rademacher J. et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial // Blood.– 2018.– Vol. 132.– P. 421. doi: 10.1182/blood-2018-99-118808.

Mosarla R., Vaduganathan M., Qamar A. et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week // J. Am. Coll. Cardiol.– 2019.– Vol. 73.– P. 1336–1349. doi:

Nieto J., Solano R., Trapero I. et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism // Thromb. Res.– 2013.– Vol. 132.– P. 175–179. doi:

Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis // Blood.– 2002.– Vol. 100.– P. 3484–3488. doi:

Qdaisat A., Aiham et al. Evaluation of cancer patients with suspected pulmonary embolism: Performance of the American College of Physicians Guideline // J. Am. Coll. Radiology.– 2020.– Vol. 17 (1).– P. 22–30. doi:

Qdaisat A., Wu C., Yeung S.C. Normal D-dimer levels in cancer patients with radiologic evidence of pulmonary embolism // J. Thromb. Thrombolysis.– 2019.– Vol. 48 (1).– P. 174–179. doi:

Raskob G., van Es N., Verhamme P. et al. on behalf of the Hokusai vte Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism // New Engl. J. Med.– 2018.– Vol. 378.– P. 615–624. doi:

Siegel R., Miller K., Jemal A. Cancer statistics, 2018 // CA Cancer. J. Clin.– 2018.– Vol. 68 (1).– P. 7–30. doi:

Sousa B., Furlanetto J., Hutka M. et al on behalf of the ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines // Ann. Oncology.– 2015.– Vol. 26 (5).– P. v152–v168. doi:

Vedovati M., Germini F., Agnelli G., Becattini C. Direct oral anticoagulants in patients with vte and cancer: a systematic review and meta-analysis // Chest.– 2015.– Vol. 147.– P. 475–483. doi:

Watson H., Keeling D. et. al. Guideline on aspects of cancer-related venous thrombosis // British J. Haematol.– 2015.– Vol. 170.– P. 640–648. doi:

Young A., Marshall A., Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (Select-D) // J. Clin. Oncol.– 2018.– Vol. 36.– P. 2017–2023. doi:

Zamorano J.L., Lancellotti P. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines // Eur. Heart J.– doi: 211.

Most read articles by the same author(s)